ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

2.14
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.14 2.10 2.18 2.20 2.19 2.19 604,698 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.93 7.33M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.14p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7.33 million. Immupharma has a price to earnings ratio (PE ratio) of -1.93.

Immupharma Share Discussion Threads

Showing 36401 to 36422 of 39125 messages
Chat Pages: Latest  1457  1456  1455  1454  1453  1452  1451  1450  1449  1448  1447  1446  Older
DateSubjectAuthorDiscuss
14/5/2020
12:42
Imm has no debt. Littlepup filtered
wigwammer
14/5/2020
11:59
Response from Immunology Institute of the Icahn School of Medicine, Mount Sinai 4 days ago to Emory University research findings ...

Referring to the significance of their findings ...

Using a specialized flow cytometry panel for B cell analysis, the authors provide a description of the B cell landscape in COVID-19 patients. Understanding the role of potentially pathogenic B cell modules could be crucial for designing immuno-modulatory therapies that target pro-inflammatory or potentially autoimmune phenotypes seen with SARS-CoV-2 infections.

Immupharma - whole raison d’etre is immuno-modulatory therapies.

Maybe Nobby can duck out from bickering long enough to provide his detailed assessment of this Emory study and Mount Sinai review?

borromini1
14/5/2020
11:20
The bounce back after the GAP is on
Buys are now pouring in

master rsi
14/5/2020
11:12
Dave. Avion, the cnrs and the fda know what they're talking about - and the day before the ph3 results are read out, that is the opinion the market will be pricing in. Not the opinion of some self appointed guru on the ADVFN chat board. ImmuPharma is now largely funded to get to that result and I suspect we will see an exponential rerating prior to readout which will offer multiple profit taking stages. Atb
wigwammer
14/5/2020
10:56
Responses to US Emory University Research article released on 3 May include Alex Woodruff ...

Important new research out of @EmoryUniversity. Critically ill patients with #COVID19 show lupus-like b-cell activation. This may help us understand the large racial disparities in death numbers and guide treatment for those vulnerable!

Somebody tell Matt and Boris!

borromini1
14/5/2020
10:51
I know you guys hate the fact that I know what I am talking about. Twenty eight years in the Pharma industry working at all stages of drug development in rheumatology and gastroenterology has given me exactly the correct sort of experience to be able to assess Lupuzor and other drugs!

So sorry about that....

nobbygnome
14/5/2020
10:43
Lol. Let him talk to himself for a while :)
wigwammer
14/5/2020
10:37
Point Nobby..

About today's news ? Don't you think Tim just ramped up this share as usual.

To ride this wave I bought today to trade it out but when I read RNS i laughed like anything.

Every other Pharma company coming up with COVID RNS it seems.

idontflykathyy
14/5/2020
10:33
As we have discussed before the FDA really are not that concerned about efficacy; safety is the key issue for them. If you can convince them you have a half decent plan, they will let you go ahead. It is no skin off their nose if the drug fails and indeed they still collect all the fees involved! I have been present in those meetings myself so know what I am talking about....
nobbygnome
14/5/2020
10:26
Bought again at 18P

cmon IMM - I'm here for a day or two trade.

Dont disappoint me lol

idontflykathyy
14/5/2020
10:25
Opening at 16.50p UT this morning has created a GAP it has now been filled, some good chance of moving higher again.
master rsi
14/5/2020
10:10
"IMHO"... exactly...in nob's opinion. But not in the opinion of avion, the cnrs, or the fda.
wigwammer
14/5/2020
10:07
>> wiggy

Still virtually no chance of it working IMHO! Avion are like lambs to the slaughter....

nobbygnome
14/5/2020
10:04
Cmon IMM reach to 25P and I exit..

What a shame as according to few LSE member this is 40P share lol

idontflykathyy
14/5/2020
10:03
ie the people that count.
wigwammer
14/5/2020
10:03
Lupuzor is probably going back into phase 3. This suggests that avion, the cnrs, the fda, and all the other people required to get it into phase 3 don't agree with you.
wigwammer
14/5/2020
10:00
Lupuzor working in any indication would be more of a miracle....
nobbygnome
14/5/2020
09:56
I'm interested in a miracle, nob. That your good friend Kathy from Malta has suddenly lost all trace of spanglish. Alleluia! :)
wigwammer
14/5/2020
09:52
A super scientist with flawed alter egos who can save the Dow - I'm on the blower to Marvel.
daveboy1
14/5/2020
09:45
Why only stop at 25% ?

Guys we need to pump more

idontflykathyy
14/5/2020
09:43
Very strange question. Isn't talking about IMM on an IMM thread slightly more relevant....
nobbygnome
14/5/2020
09:39
Never mind that. Did you say Kathy was from Malta?
wigwammer
Chat Pages: Latest  1457  1456  1455  1454  1453  1452  1451  1450  1449  1448  1447  1446  Older

Your Recent History

Delayed Upgrade Clock